It's an important win for a drug gained in the Celgene acquisition to reach blockbuster status.
News & Analysis: Bristol Myers Squibb
If it's steadiness you're after, these two healthcare giants have shown they can perform during a pandemic and beyond.
One is growing revenue. And the other may soon launch its first product.
Warren Buffett is a legendary investor, but he's wrong to pare down these top-tier stocks.
They're safe companies that also regularly raise their payouts.
These two companies should be on your radar.
Our constant need for medical products will be a major growth driver for these healthcare giants.
LAG-3 is the new PD-1.
Investors will have to wait for the full data set to see how much the drug could really help cancer patients.
Abecma is on the market.